Clare Ozawa
QuietNamed in filings at Versant VantageOn the current fund
- Board seats filed
- 8
- Named on a board
- 0
all filings on record
Named in filings at Versant VantageOn the current fund
all filings on record
last 24 months
from a verified or cited source
| March Therapeutics | Biotech & pharma | September 2022 | Versant Venture Capital |
| Lenz Therapeutics | Biotech & pharma | October 2020 | Versant Venture Capital |
| Jengu Therapeutics | Biotech & pharma | September 2020 | Versant Venture Capital |
| Lycia Therapeutics | Biotech & pharma | March 2020 | Versant Venture Capital |
| 858 Therapeutics | Biotech & pharma | March 2020 | Versant Venture Capital |
| Oyster Point Pharma | Biotech & pharma | February 2019 | Versant Venture Capital |
| Inception IBD | Biotech & pharma | December 2015 | Versant Venture Capital |
| Mistral Therapeutics | Not yet classified | May 2011 | Versant Venture Capital |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The sector is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Classified sectors of companies where filings name Clare Ozawa on the board, based on 7 filed seats with a verified or cited source.
1 more filed seat not yet classified, left out of the shares above.